CN115677634B - Red yeast yellow pigment with anticancer function - Google Patents
Red yeast yellow pigment with anticancer function Download PDFInfo
- Publication number
- CN115677634B CN115677634B CN202110583103.5A CN202110583103A CN115677634B CN 115677634 B CN115677634 B CN 115677634B CN 202110583103 A CN202110583103 A CN 202110583103A CN 115677634 B CN115677634 B CN 115677634B
- Authority
- CN
- China
- Prior art keywords
- yellow pigment
- mycelium
- monascus
- monascus yellow
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001052 yellow pigment Substances 0.000 title claims abstract description 24
- 230000001093 anti-cancer Effects 0.000 title abstract description 15
- 229940057059 monascus purpureus Drugs 0.000 title description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 35
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 13
- 239000012074 organic phase Substances 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 208000023445 Congenital pulmonary airway malformation Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims 1
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 abstract description 5
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 abstract description 5
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000031003 Monascus ruber Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002152 aqueous-organic solution Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention belongs to the field of compounds, and particularly relates to monascus yellow pigment with an anticancer function. The specific technical scheme is as follows: a new monascus yellow pigment Monascin A is provided. Experiments prove that the invention has stronger anticancer function and great potential of becoming an anticancer drug.
Description
Technical Field
The invention belongs to the field of compounds, and particularly relates to monascus yellow pigment with an anticancer function.
Background
Natural products are the main sources of new drugs, such as anticancer, anti-inflammatory, antibacterial, etc. Therefore, the development of natural products with anticancer function is of great importance. The natural product can be used as drug or precursor substance for preparing anticancer drug or related research. Currently, about 50% of anticancer drugs are derived from natural products. Numerous studies have shown that the anticancer effect of natural compounds is versatile and mainly comprises: directly inhibit cancer cell growth, resist oxidation and free radical, block cancer cell division cycle, induce tumor cell apoptosis, inhibit protein kinase activity, inhibit signal transduction, inhibit topoisomerase, etc. Therefore, the discovery of new anticancer natural compounds is of great importance.
Disclosure of Invention
The invention aims to provide monascus yellow pigment with an anticancer function.
In order to achieve the aim of the invention, the invention adopts the following technical scheme: a monascus yellow pigment has a molecular formula: c (C) 15 H 18 O 4 The molecular structural formula is as follows:
correspondingly, the monascus yellow pigment preparation method is characterized in that monascus strain M7 is prepared by fermentation, and monascus strain M7 is preserved in a laboratory of collection and preservation focus of agricultural microorganism resources, wherein the preservation number is: CCAM No.070120.
Preferably, the method for extracting monascus yellow pigment after fermentation comprises the following steps: soaking mycelium obtained after fermentation of the monascus strain M7 by HCl, extracting the mycelium by using an organic solvent to obtain a water phase-organic phase two-phase solution, separating a water phase solution, removing pigments in the organic phase, drying, and removing the organic solution.
Preferably, the organic solvent is a mixed solution of ethyl acetate and acetone.
Preferably, the method for extracting monascus yellow pigment after fermentation comprises the following steps: after the mycelium is soaked in HCl, the mycelium is washed once by clear water, the mycelium is collected by filtration, and then the mycelium is mixed with an organic solvent.
Preferably, the organic solvent is mixed with the mycelium to obtain a mixture, the mixture is heated to 60 ℃, the mixture is subjected to shaking extraction, and the mycelium is removed by filtration through nylon filter cloth to obtain the aqueous-organic phase two-phase solution.
Preferably, the method for removing pigments in the organic phase is as follows: adding macroporous resin into the organic phase, and removing pigment by vibration adsorption.
Preferably, the method for extracting monascus yellow pigment after fermentation comprises the following steps: after the organic solution was removed, the obtained product was redissolved with methanol to obtain a methanol solution, and the methanol solution was separated and purified by a semi-preparative liquid chromatograph.
Correspondingly, the monascus yellow pigment is applied to the preparation of anticancer drugs.
The invention has the following beneficial effects: the invention discovers and purifies a novel compound Monascin A from monascus with homology of traditional food and medicine. The molecular structure is determined by NMR and LC-MS, and experiments prove that the medicine has stronger anticancer and antibacterial functions and great potential of becoming an anticancer antibacterial medicine.
Drawings
FIG. 1 is a nuclear magnetic resonance hydrogen spectrum of Monospin A;
FIG. 2 is a nuclear magnetic resonance carbon spectrum of Monospin A.
Detailed Description
The invention provides a new monascus yellow pigment Monascin A, C 15 H 18 O 4 The molecular structural formula is as follows:
the Monospin A has a strong anticancer function.
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. The technical means used in the examples are conventional means well known to those skilled in the art unless otherwise indicated.
Embodiment one: preparation, extraction and identification of Monospin A
1. Monascus strain M7 (collection and preservation of agricultural microbial resources from the Ministry of agriculture, accession number: CCAM No.070120, first published in Extremophiles (2016) 20:451-459, cloning, expression and characterization of a novel cold-active and organic solvent-tolerant esterase from Monascus ruber M). Incidentally, the inventors tried various Monascus rubers, and Monascin A was only found and extracted in M7 at present.
The monascus strain M7 was inoculated onto a fresh PDA medium, cultured at 30 ℃ for 10 days, and monascus mycelia were washed with sterile water to obtain monascus spore liquid. Diluting Monascus spore liquid to 1×10 with sterile water 5 And each mL. Taking 2mL of diluted monascus spore liquid, inoculating into 30mL of fresh PDB culture medium, and heating at 30deg.CCulturing at 150rpm for 15 days, filtering with nylon filter screen, discarding filtrate, and collecting mycelium.
2. Mycelium is soaked in 0.1mol/L HCl solution at 30 ℃ for 1h, then filtered, and the filtrate is discarded to obtain mycelium. Washing the mycelium once with clear water, removing HCl adsorbed on the surface of the mycelium, and filtering to collect the mycelium. Mixing with wet mycelium with organic solvent (ethyl acetate: acetone=3:1, volume ratio) to obtain mixture; the ratio of organic solvent to wet mycelium was 30mL:1g of wet mycelium. The mixture was heated to 60℃and extracted with shaking at 50rpm for 3 hours. The mycelium was removed by filtration through nylon filter cloth to give a two-phase aqueous-organic solution. The two-phase solution was separated using a separating funnel, and the aqueous phase was discarded to obtain an organic phase. Then, 3g of a wet macroporous resin (model LSA-7) was added to about 30mL of the obtained organic solvent, and the mixture was shaken at 30℃and 50rpm to adsorb most of the dye molecules by the resin. Then filtering to remove resin particles to obtain organic solvent, concentrating the organic solvent in the organic phase to 1/10 by vacuum distillation, and using anhydrous Na 2 SO 4 The water was removed, and then the whole organic solution was distilled off under reduced pressure to obtain a solid. The obtained solid was dissolved with methanol to obtain a methanol solution.
3. Separating and purifying the methanol solution by a semi-preparative liquid chromatograph. Semi-preparative liquid chromatograph model was Waters, U.S.A., semi-preparative column was InertsilODS-3 (250 mm. Times.10 mm,5 μm). The prepared sample solution was added to the sample inlet at a sample injection amount of 100 μl, a flow rate of 3mL/min, methanol and water as mobile phases, and an initial mobile phase to methanol: water=1:1, column temperature of 25 ℃, PDA detector. And determining a product peak through the retention time, and collecting an eluting component in time to obtain the Monospin A sample with the purity of more than 95%. The sample was dried with a nitrogen blower to give 84 μg of yellow solid powder.
4. The structure of the compound is identified by using NMR (nuclear magnetic resonance) and GC-MS (gas chromatography-mass spectrometry) technologies, a nuclear magnetic resonance hydrogen spectrum is shown in figure 1, and a nuclear magnetic resonance carbon spectrum is shown in figure 2.
Embodiment two: monospin A anticancer effect display
1. And the effect of inhibiting the growth of cancer cells is displayed.
Liver cancer cell line QGY-7701 and lung cancer cell line SPC-A-1 were selected as subjects for testing Monospin A inhibition of cancer cell growth experiments. Two cancer cell lines were inoculated into RPMI-1640 medium (available from Semer Feishul technologies (China)) at 37℃and 5% CO 2 Cells were collected by centrifugation in a constant temperature incubator until log phase, resuspended in buffer, and added to 96-well plates at 180 μl (about 6000 cells/well) per well. Placing the 96-well plate in a constant temperature incubator at 37deg.C with 5% CO 2 Culturing was performed under the same conditions for 14 hours, and then different concentrations of Monospin A (5, 10, 15 or 20. Mu.M) were added to the different wells, respectively, and culturing was continued under the same conditions for 24 hours.
In each well, 100. Mu.L of cell-free supernatant was carefully removed, and 90. Mu.L of fresh serum medium and 10. Mu.L of MTT reagent were added, and the incubation was continued for 4 hours after mixing well. After removing 110. Mu.L of the cell-free supernatant again, 110. Mu.L of Formazan reagent was added thereto, and the mixture was shaken at a low speed for 10 minutes to complete mixing. Finally, the absorbance of each well was measured at 490nm, and the concentration inhibiting the growth of 50% cancer cells, i.e., half inhibition concentration (IC 50), was calculated. The results show that Monospin A has an IC50 of 11.10 μm for liver cancer cell line QGY-7701 and an IC50 of 12.54 μm for lung cancer cell line SPC-A-1, and shows strong cancer cell inhibition.
2. Animal experiments with anticancer effect show.
SD rats used, weighing about 200g, purchased from Shanghai Laek laboratory animals Co., ltd, were induced to develop liver tumors after one week of adaptive feeding, starting with water containing Diethylnitrosamine (DEN). The following groupings were randomly made for 10 rats with insignificant differences in each group, selected from DEN cancer-induced rats for 14 weeks: (1) control group (blank group, no drug); (2) Monospin A group (2 mg/kg). The administration is carried out once a week along with the feeding of the feed for four weeks. At week 19, each group of rats was sacrificed and tissue specimens were obtained. According to liver anatomy results, the number of tumors (tumor mass > 0.5cm in diameter) in rat liver of Monospin A group was smaller than that of control group, about 60% of control group, and the tumor volume was smaller, about 50% of control group. Monospin A was demonstrated to significantly inhibit tumor growth in rats.
Embodiment III: monospin A antibacterial effect display
For bacteria, a loop of bacteria solution was picked from the glycerol-preserving tube with an inoculating loop and inoculated into 10mL of LB medium. Then, the strain was placed in an incubator and cultured with shaking at 37℃and 180rpm for 18 hours to place the strain in the logarithmic phase of growth. Then 1mL of the bacterial liquid was diluted with fresh LB medium, and the absorbance (OD) of the bacterial liquid at 620nm was measured 620 ) Adjusting the concentration of the bacterial liquid to make OD 620 Between 0.09 and 0.11, the concentration of the bacterial liquid is about 5 multiplied by 10 8 CFU/mL. For the filamentous fungi, the strains are inoculated on PDA culture medium and cultured for 5-10 days at 30 ℃ until the colony diameter is more than 2cm. Then inoculating the pre-cultured strain to a fresh PDA culture medium, culturing for 5-10 days at 30 ℃, and washing mycelium with sterile water to obtain spore liquid. Diluting the spore liquid with sterile water, and detecting spore liquid concentration under microscope with blood cell counting plate to about 1×10 5 And each mL.
198. Mu.L of bacterial or filamentous fungal spore solution was added to one well of a 96-well plate using a sterile pipette, then 2. Mu.L of Monospin A solution (2.0 mg/mL) was added to the first well and mixed well with shaking, the Monospin A concentration in the well being 20. Mu.g/mL. Using this dilution method, 5 treatments were set at Monospin A concentrations of 20, 10, 5, 2.5 and 1.25. Mu.g/mL, respectively. And a negative control group was set: 2. Mu.L of methanol was added to 198. Mu.L of the bacterial or spore solution. After the 96-well plate for the bacterial inhibition test was placed in an incubator at 37℃for 24 hours, absorbance was measured at 620nm using a microplate reader, and the minimum Monospin A concentration when the microbial growth was completely inhibited and no longer grown was the Minimum Inhibitory Concentration (MIC) of Monospin A. As a result, monascin A had MIC's for E.coli, pseudomonas aeruginosa, staphylococcus aureus, and Salmonella of 11.2 μg/mL, 20.1 μg/mL, 17.4 μg/mL, and 5.8 μg/mL, respectively; MIC for Aspergillus flavus, aspergillus fumigatus, aspergillus nidulans was 30.3. Mu.g/mL, 26.8. Mu.g/mL, and 25.4. Mu.g/mL, respectively. Has obvious effect of inhibiting the growth of bacteria and fungi.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications, variations, alterations, substitutions made by those skilled in the art to the technical solution of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the spirit of the design of the present invention.
Claims (8)
1. A monascus yellow pigment, which is characterized in that: the molecular formula is: c (C) 15 H 18 O 4 The molecular structural formula is as follows:
。
2. the method for preparing monascus yellow pigment as claimed in claim 1, wherein: the monascus strain M7 is prepared by fermentation, and the monascus strain M7 is preserved in a laboratory of collection and preservation focus of agricultural microorganism resources of the Ministry of agriculture, wherein the preservation number is: CCAM No.070120.
3. The method for preparing monascus yellow pigment according to claim 2, wherein: after fermentation, the method for extracting the monascus yellow pigment comprises the following steps: soaking mycelium obtained after fermentation of the monascus strain M7 by HCl, extracting the mycelium by using an organic solvent to obtain a water phase-organic phase two-phase solution, separating and removing water phase liquid, removing pigment impurities in the organic phase, drying, and removing the organic solution; the organic solvent is a mixed solution of ethyl acetate and acetone.
4. A process for the preparation of monascus yellow pigment according to claim 3, wherein: after fermentation, the method for extracting the monascus yellow pigment comprises the following steps: after the mycelium is soaked in HCl, the mycelium is washed once by clear water, the mycelium is collected by filtration, and then the mycelium is mixed with an organic solvent.
5. A process for the preparation of monascus yellow pigment according to claim 3, wherein: mixing the organic solvent with the mycelium to obtain a mixture, heating the mixture to 60 ℃, carrying out shaking extraction, and filtering with nylon filter cloth to remove the mycelium to obtain the aqueous phase-organic phase two-phase solution.
6. A process for the preparation of monascus yellow pigment according to claim 3, wherein: the method for removing the pigment in the organic phase comprises the following steps: adding macroporous resin into the organic phase, and removing pigment by vibration adsorption.
7. A process for the preparation of monascus yellow pigment according to claim 3, wherein: after fermentation, the method for extracting the monascus yellow pigment comprises the following steps: after the organic solution was removed, the obtained product was redissolved with methanol to obtain a methanol solution, and the methanol solution was separated and purified by a semi-preparative liquid chromatograph.
8. The use of monascus yellow pigment according to claim 1 for the preparation of anticancer drugs, characterized in that: the medicine is an anti-liver cancer medicine or an anti-lung cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110583103.5A CN115677634B (en) | 2021-07-21 | 2021-07-21 | Red yeast yellow pigment with anticancer function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110583103.5A CN115677634B (en) | 2021-07-21 | 2021-07-21 | Red yeast yellow pigment with anticancer function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115677634A CN115677634A (en) | 2023-02-03 |
| CN115677634B true CN115677634B (en) | 2023-12-12 |
Family
ID=85044701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110583103.5A Active CN115677634B (en) | 2021-07-21 | 2021-07-21 | Red yeast yellow pigment with anticancer function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115677634B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862324B (en) * | 2010-04-13 | 2012-05-30 | 福州大学 | Application of monascus color components and derivatives thereof in fighting cancers |
-
2021
- 2021-07-21 CN CN202110583103.5A patent/CN115677634B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862324B (en) * | 2010-04-13 | 2012-05-30 | 福州大学 | Application of monascus color components and derivatives thereof in fighting cancers |
Non-Patent Citations (3)
| Title |
|---|
| Cloning, expression and characterization of a novel cold‑active and organic solvent‑tolerant esterase from Monascus ruber M7;Hailun Guo et al.;《Extremophiles》;第20卷;451-459 * |
| 液态发酵红曲黄色素粗提物色素组分的分离纯化与鉴定;徐菲菲 等;《食品与发酵工业》;第46卷(第1期);91-98 * |
| 红曲菌菌株 M7 的生物学特性研究;王小莉 等;《中国热带医学》;第5卷(第6期);1349-1350 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115677634A (en) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103740606B (en) | Plant raw streptomycete and produce antibiotic promise and irrigate method and the application of nest mycin | |
| CN106434372B (en) | Application of coral-derived fungus aspergillus terreus strain C21-10 | |
| CN114956993B (en) | Antibacterial compound derived from trichoderma hook and application thereof | |
| CN101720772B (en) | Macrolide composition for preventing and controlling fungal disease of crop and preparation process thereof | |
| CN113005048B (en) | Streptomyces nigricans CYS22, metabolite thereof and application thereof | |
| CN111778172B (en) | Streptomyces for producing antibacterial active compound and separation method and application thereof | |
| CN110590769B (en) | Pair of quinazolinone alkaloid enantiomers, preparation method and application thereof | |
| CN115677634B (en) | Red yeast yellow pigment with anticancer function | |
| CN108191663B (en) | Antagonistic rice bacterial leaf blight active monomer compound and preparation method thereof | |
| CN107488594B (en) | New penicillium and metabolite antacid A thereof | |
| CN109180593B (en) | Phenolic oxazine alkaloid secondary metabolite and application thereof | |
| CN108794502B (en) | Trichothecene compound and preparation method and application thereof | |
| CN112961783A (en) | Plant endophytic fungus and application thereof in preparation of spironolactone derivative | |
| CN103820332A (en) | Huperzia serrata endophytic fungi as well as method and application of huperzia serrata endophytic fungi for producing huperzine A | |
| CN115044483B (en) | Penicillium fungus W21C371 and application thereof in preparation of curvulin | |
| CN109971655B (en) | Astragalus membranaceus endophytic Chaetomium sp HQ-1 and application thereof | |
| CN108660169A (en) | A method of fermentation prepares spine spore bacteriums antibiotic | |
| CN113151073B (en) | Giraldii annulata producing strain and purification preparation and application of pigment thereof | |
| CN114806888B (en) | Aspergillus versicolor ZJUTE2 and application thereof in preparation of aflatoxin | |
| CN117305388B (en) | Application of bacillus bailii SL-K2 in preparation of guanine extract, preparation method of guanine extract and application | |
| CN112159777B (en) | Cyclopeptide antibiotic valinomycin high-yield strain and application thereof | |
| CN109251145B (en) | Phthalate, and preparation method, strain and application thereof | |
| CN107652305B (en) | A kind of indoles cyanoalkaloids compound and its preparation and application | |
| CN109912623B (en) | Xanthone compound, preparation method and application thereof | |
| CN107652262B (en) | Preparation method and application of amicumacecin isocoumarin compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |